arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ANAVEX LIFE SCIENCES CORP.

AVXL
$3.35 ▲ +0.06 (+1.82%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
83 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

ANAVEX LIFE SCIENCES CORP. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $298.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -4.2%
FCF / Share $-0.08
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

83-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.68M
↑ +53.1%
FCF / Share Free cash flow per share
$-0.08
↑ +43.8%
Long-Term Debt Long-term obligations
$345.00
↑ +2.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
17
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 22 years · 83 quarters